Basilea Pharmaceutica AG (BSLN.SW)

CHF 41.65

(0.24%)

Revenue Summary of Basilea Pharmaceutica AG

  • Basilea Pharmaceutica AG's latest annual revenue in 2023 was 157.63 Million CHF , up 6.68% from previous year.
  • Basilea Pharmaceutica AG's latest quarterly revenue in 2024 Q2 was 76.29 Million CHF , down 0.0% from previous quarter.
  • Basilea Pharmaceutica AG reported a annual revenue of 147.76 Million CHF in annual revenue 2022, down -0.24% from previous year.
  • Basilea Pharmaceutica AG reported a annual revenue of 148.12 Million CHF in annual revenue 2021, up 16.06% from previous year.
  • Basilea Pharmaceutica AG reported a quarterly revenue of 72.72 Million CHF for 2023 Q4, down 0.0% from previous quarter.
  • Basilea Pharmaceutica AG reported a quarterly revenue of 84.9 Million CHF for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Basilea Pharmaceutica AG (2023 - 2002)

Historical Annual Revenue of Basilea Pharmaceutica AG (2023 - 2002)

Year Revenue Revenue Growth
2023 157.63 Million CHF 6.68%
2022 147.76 Million CHF -0.24%
2021 148.12 Million CHF 16.06%
2020 127.62 Million CHF -5.02%
2019 134.38 Million CHF 1.38%
2018 132.55 Million CHF 30.57%
2017 101.52 Million CHF 53.86%
2016 65.98 Million CHF 24.91%
2015 52.82 Million CHF 24.3%
2014 42.49 Million CHF 3.78%
2013 40.95 Million CHF -29.8%
2012 58.33 Million CHF -11.81%
2011 66.14 Million CHF -42.75%
2010 115.55 Million CHF 330.72%
2009 26.82 Million CHF 124.05%
2008 11.97 Million CHF 51.6%
2007 7.89 Million CHF 9.95%
2006 7.18 Million CHF -76.44%
2005 30.49 Million CHF 10536.38%
2004 286.7 Thousand CHF -24.4%
2003 379.22 Thousand CHF 85.58%
2002 204.34 Thousand CHF 0.0%

Peer Revenue Comparison of Basilea Pharmaceutica AG

Name Revenue Revenue Difference
Addex Therapeutics Ltd 1.61 Million CHF -9647.413%
BB Biotech AG -199.56 Million CHF 178.988%
Evolva Holding SA 9.43 Million CHF -1570.241%
Idorsia Ltd 152.38 Million CHF -3.444%
Kuros Biosciences AG 33.56 Million CHF -369.652%
Molecular Partners AG 7.03 Million CHF -2139.756%
Relief Therapeutics Holding AG 6.03 Million CHF -2512.863%
Santhera Pharmaceuticals Holding AG 103.41 Million CHF -52.43%